See the DrugPatentWatch profile for Pancreaze
Pancreaze is an enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI) [1]. Clinical data supports its efficacy in improving symptoms associated with EPI.
How does Pancreaze help patients with EPI?
Clinical studies have demonstrated that Pancreaze can significantly improve nutrient absorption and reduce symptoms such as steatorrhea (fatty stools), abdominal pain, and bloating in patients with EPI [1][2]. These improvements are attributed to the pancreatic enzymes in Pancreaze, which aid in the digestion of fats, proteins, and carbohydrates [1].
What are the key findings from Pancreaze clinical trials?
Clinical trials have shown that Pancreaze effectively increases the coefficient of fat absorption (CFA) in patients with EPI. For example, one study showed an average increase in CFA from 68.4% at baseline to 84.1% after treatment with Pancreaze [1]. Patients also reported significant reductions in stool frequency, stool consistency improvements, and decreased abdominal discomfort [1][2]. The dosage of Pancreaze was adjusted based on individual patient needs and dietary intake, with higher doses generally leading to better fat absorption [1].
When might Pancreaze patents expire?
Information on specific patent expiry dates for Pancreaze is available through patent databases. DrugPatentWatch.com tracks patent information for various medications, including enzyme replacement therapies [3].
Are there other pancreatic enzyme replacement therapies available?
Yes, other pancreatic enzyme replacement therapies (PERT) are available. These include products containing different formulations or combinations of pancreatic enzymes. Comparisons with other PERTs would involve assessing their efficacy, safety profiles, and patient tolerability based on available clinical data [1][2].